Mechanism of Action
GP IIb/IIIa (alphaIIbbeta3) Blockade
GP IIb/IIIa is the most abundant platelet surface receptor (~80,000 copies/platelet). Upon platelet activation, conformational changes expose the fibrinogen-binding site on GP IIb/IIIa. Fibrinogen bridges GP IIb/IIIa receptors on adjacent platelets, forming the platelet aggregate. Eptifibatide's cyclic KGD sequence mimics the RGD and KQAGDV sequences of fibrinogen that bind GP IIb/IIIa, competitively inhibiting fibrinogen binding and preventing platelet-fibrinogen-platelet cross-linking. This blocks the final aggregation step regardless of upstream activation pathway.
Rapid Onset and Reversibility
Eptifibatide inhibits >80% of ADP-induced platelet aggregation within 15 minutes of IV bolus. Inhibition is dose-proportional and reversible, upon stopping the infusion, platelet aggregation recovers to >50% within 4 hours. This reversibility is a key advantage in acute care settings where procedural bleeding risk needs rapid management. The short half-life (2.5 hours) and low molecular weight allow quick drug elimination without specific reversal agents.
RGD Peptide Biology
The RGD integrin-binding motif is one of the most important cell adhesion sequences in biology, found in fibronectin, vitronectin, fibrinogen, von Willebrand factor, and many other matrix proteins. Eptifibatide's cyclic KGD variant achieves alphaIIbbeta3 selectivity over other RGD-binding integrins (alpha5beta1, alphavbeta3). This selectivity research informed development of RGD-based biomaterials, cell attachment surfaces, and targeted drug delivery systems far beyond antiplatelet therapy.
Research Summary
ACS and PCI (Historical Standard)
ClinicalPURSUIT trial (n=10,948) showed eptifibatide reduced 30-day death/MI by 9.9% vs 11.0% placebo in NSTEMI. ESPRIT trial in elective PCI showed 6.6% vs 10.5% reduction in composite endpoint. These trials established GP IIb/IIIa inhibitors as standard therapy for high-risk ACS and PCI in the 1990s-2000s. With the availability of ticagrelor and prasugrel (more potent oral P2Y12 inhibitors), the role of GP IIb/IIIa inhibitors has narrowed to high-risk NSTEMI/PCI where additional platelet inhibition is needed despite adequate P2Y12 loading.
Integrin Biology Research
Research ToolEptifibatide and related RGD peptides are used to study integrin signaling, platelet biology, and cell-matrix interactions. Cyclic RGD peptides derived from this work have been incorporated into biomaterials for tissue engineering to promote cell adhesion and differentiation. RGD-drug conjugates targeting integrin-expressing cells (tumors, angiogenic endothelium) are a direct descendant of eptifibatide/disintegrin research.
Stroke and Clot Dissolution
ResearchEptifibatide combined with low-dose tissue plasminogen activator (t-PA) has been studied in ischemic stroke (CLEAR trial) for clot dissolution at reduced t-PA doses to minimize hemorrhagic transformation. The combination showed some signal for improved outcomes in middle cerebral artery occlusions. These data informed exploration of GP IIb/IIIa inhibitors as adjuncts to thrombolysis in select stroke populations, though definitive clinical adoption has not occurred.
Calculate your Eptifibatide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| PCI (high-risk) | 180 mcg/kg IV bolus x2 (10 min apart); 2 mcg/kg/min infusion for 18-24h | IV bolus then continuous infusion | IV |
| NSTEMI (medical management) | 180 mcg/kg IV bolus; 2 mcg/kg/min infusion for 72-96h or until discharge | IV bolus then continuous | IV |
| Platelet aggregation inhibition (research) | 0.1-10 mcg/mL ex vivo | Single concentration | Added to platelet-rich plasma |
Dose reduce in renal impairment (CrCl <50: reduce infusion to 1 mcg/kg/min). Monitor aPTT and platelet count. No reversal agent - stop infusion and allow natural clearance for bleeding.
Interactions
Safety Profile
The primary adverse effect is bleeding, major bleeding rates 1-10% depending on vascular access, concomitant anticoagulation, and patient risk factors. Intracranial hemorrhage is rare (<0.2%). Thrombocytopenia occurs acutely in ~0.5% (within 24 hours of starting infusion) - check platelet count 6 hours post-initiation. Unlike abciximab (a murine-derived antibody), eptifibatide is synthetic and has minimal immunogenicity. Platelet function recovers within 4-6 hours of stopping infusion. Contraindicated in severe bleeding, recent surgery, or prior GP IIb/IIIa inhibitor thrombocytopenia.
References
- [1]Harrington RA, et al. Antiplatelet therapy with eptifibatide in patients with non-Q-wave acute coronary syndromes: PURSUIT trial. N Engl J Med. 1998.
- [2]Tcheng JE, et al. Outcomes of patients treated with tirofiban or eptifibatide in clinical trials: review of available data. Am Heart J. 2002.
- [3]Scarborough RM, et al. Barbourin: a GP IIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991.